For a decade, Kendall Square operated as the tightest commercial real estate market in the United States. Vacancy rates for laboratory space hovered below 2 percent. Asking rents exceeded $100 per square foot triple-net — a price point that would have been considered absurd for any asset class other than the specialized wet-lab facilities that pharmaceutical and biotechnology companies require for drug development. Developers responded by building: between 2020 and 2025, more than 10 million square feet of new laboratory space was delivered or commenced construction in the greater Kendall Square area, extending into Somerville's Inner Belt, the Alewife corridor, and the Watertown Arsenal complex. The building continued after the demand signal changed. The biotech funding winter of 2022-2024, which saw venture capital investment in life sciences decline by approximately 40 percent from its 2021 peak, arrived while the construction pipeline was at its deepest. The result is a market in correction — a tenant's market for the first time in a generation, with implications for rents, concession packages, sublease dynamics, and the commercial real estate portfolios of every institutional investor who underwrote Kendall Square at peak valuations.
The Vacancy Shift
Laboratory vacancy in Greater Cambridge rose from 1.8 percent in the fourth quarter of 2021 to approximately 12 percent by early 2026 — a six-fold increase that compressed the timeline of a typical real estate cycle into three years. The increase was driven by the simultaneous arrival of new supply (developers delivering the projects they had started during the boom) and the contraction of demand (biotechnology companies reducing their space requirements as funding tightened, clinical programs failed, and headcount was cut).
The sublease market — space that existing tenants are offering to sublet because they no longer need it — provides the most granular measure of the demand contraction. Sublease availability in Greater Cambridge exceeded 3 million square feet in 2025, up from approximately 400,000 square feet in 2021. Sublease space is typically offered at 20 to 40 percent below direct lease rates because the sublessee assumes the incumbent tenant's build-out (saving the time and capital expenditure of a new construction fit-out) and the lease term is shorter (the sublease expires when the prime lease expires, regardless of the sublessee's preference). For tenants seeking flexible, cost-efficient space, the sublease market is a windfall. For the landlords whose direct-lease economics depend on asking rents that the sublease market is undercutting, it is a competitive threat that operates within their own buildings.
Tenant Improvement Allowances: The New Negotiating Terrain
The shift from a landlord's market to a tenant's market has transformed the economics of new lease negotiation. In the 2019-2021 peak, landlords offered tenant improvement allowances — the capital contribution toward the cost of building out a raw space to laboratory specification — of $100 to $150 per square foot. Tenants accepted the terms because the alternative was no space at all.
In the current market, tenant improvement allowances have expanded to $200 to $300 per square foot for credit-worthy tenants signing long-term leases. Landlords are competing for a smaller pool of expanding tenants by offering more generous build-out subsidies, longer free-rent periods (six to twelve months of rent abatement at the beginning of the lease term), and flexible termination rights that allow tenants to exit before lease expiration if their clinical programs fail or their funding environment deteriorates.
The increased concessions compress the landlord's effective rent — the actual revenue received per square foot per year after accounting for free rent, tenant improvements, and leasing commissions. A lease with a $90 asking rent, twelve months of free rent on a ten-year term, and a $250 TI allowance produces an effective rent of approximately $60 to $65 per square foot — a figure that may not cover the landlord's debt service, operating costs, and required return on equity. The gap between asking rent and effective rent is the measure of the market's distress, and in Kendall Square, that gap is wider than it has been since the financial crisis.
The Conversion Question: Lab to Office
Developers who built laboratory space at peak valuations now face a strategic question: should underperforming lab buildings be converted to conventional office use to capture whatever demand exists in the general office market? The answer is almost always no — for structural reasons that illuminate why laboratory real estate is a distinct asset class.
Laboratory construction costs approximately $800 to $1,200 per square foot, compared to $400 to $600 for conventional office space. The premium reflects the specialized infrastructure that laboratories require: reinforced floor loads (to support equipment weighing thousands of pounds), enhanced HVAC systems (to maintain the temperature, humidity, and air-change rates that scientific work demands), chemical-resistant plumbing and drainage, dedicated emergency power, and vivarium facilities for animal research. Converting a lab to an office means abandoning infrastructure that cost $200 to $400 per square foot to install — infrastructure that has no value in an office context but could have value if life science demand recovers.
The conversion also produces an office product that competes in a market where conventional office vacancy exceeds 20 percent nationally. A converted lab-to-office building in Kendall Square would compete against purpose-built office buildings in the Back Bay, the Financial District, and the Seaport — buildings that offer superior floor plates, better natural light, and lower operating costs. The conversion is a retreat from a weak market into a weaker market, at the cost of destroying the specialized infrastructure that made the building competitive in the stronger one.
The Recovery Thesis
The life science real estate market has corrected before. The 2008-2009 financial crisis produced a similar (if less severe) vacancy increase in Kendall Square that resolved within three years as venture capital returned to the sector and clinical-stage companies expanded their operations. The current correction differs in its supply-side magnitude — the volume of new space delivered during this cycle is three to four times the volume delivered during the prior correction — but the demand-side fundamentals remain structurally positive.
The global pharmaceutical industry spends more than $250 billion annually on research and development. The majority of that spending requires physical laboratory space. The Cambridge/Boston cluster — anchored by Harvard, MIT, the Broad Institute, Dana-Farber, Massachusetts General Hospital, and the largest concentration of biotech companies in the world — remains the preeminent location for life science R&D. No competing cluster (San Francisco, San Diego, Research Triangle, Philadelphia) has replicated the density of talent, capital, and institutional knowledge that Cambridge offers.
The recovery will be uneven. Class A laboratory buildings with modern infrastructure, floor plates designed for flexibility, and locations within walking distance of the Kendall/MIT Red Line station will recover first — their tenant quality and locational premium insulate them from the worst of the vacancy. Class B and C buildings — older facilities with constrained floor plates, outdated mechanical systems, and peripheral locations — may not recover at all, and their owners face the prospect of selling at prices that do not cover the remaining mortgage balance.
The investor evaluating Kendall Square laboratory real estate today must distinguish between the cycle and the structure. The cycle is correcting — vacancy is elevated, rents are declining, concessions are expanding. The structure is intact — Cambridge remains the global capital of life science research, and the demographic, scientific, and pharmaceutical forces that created the cluster have not diminished. The cycle will pass. The question is whether the individual asset's capital structure can survive the duration of the correction.